Electromed (ELMD) 10-K 27 Aug 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Aug. 20, 2024	Dec. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-34839
Entity Registrant Name	Electromed, Inc.
Entity Central Index Key	0001488917
Entity Tax Identification Number	41-1732920
Entity Incorporation, State or Country Code	MN
Entity Address, Address Line One	500 Sixth Avenue NW
Entity Address, City or Town	New Prague
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56071
City Area Code	(952)
Local Phone Number	758-9299
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ELMD
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 83,862,301
Entity Common Stock, Shares Outstanding		8,638,917
Document Financial Statement Error Correction [Flag]	false
Auditor Name	RSM US LLP
Auditor Location	Rochester, Minnesota
Auditor Firm ID	49

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 16,080,000	$ 7,372,000
Accounts receivable (net of allowances for credit losses of $45,000)	23,333,000	24,130,000
Contract assets	719,000	487,000
Inventories	3,712,000	4,221,000
Prepaid expenses and other current assets	329,000	1,577,000
Total current assets	44,173,000	37,787,000
Property and equipment, net	5,165,000	5,672,000
Finite-life intangible assets, net	657,000	605,000
Other assets	87,000	161,000
Deferred income taxes	2,152,000	1,581,000
Total assets	52,234,000	45,806,000
Current Liabilities
Accounts payable	1,010,000	1,372,000
Accrued compensation	3,893,000	3,018,000
Income tax payable	277,000	336,000
Warranty reserve	1,567,000	1,378,000
Other accrued liabilities	930,000	1,949,000
Total current liabilities	7,677,000	8,053,000
Other long-term liabilities	12,000	86,000
Total liabilities	7,689,000	8,139,000
Shareholders’ Equity
Common stock, $0.01 par value, 13,000,000 shares authorized; 8,637,883 and 8,555,236 issued and outstanding, as of June 30, 2024 and June 30, 2023, respectively	87,000	86,000
Additional paid-in capital	20,790,000	18,788,000
Retained earnings	23,668,000	18,793,000
Total shareholders’ equity	44,545,000	37,667,000
Total liabilities and shareholders’ equity	$ 52,234,000	$ 45,806,000

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 45,000	$ 45,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	13,000,000	13,000,000
Common stock, issued	8,637,883	8,555,236
Common stock, outstanding	8,637,883	8,555,236

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net revenues	$ 54,716,000	$ 48,067,000
Cost of revenues	12,990,000	11,548,000
Gross profit	41,726,000	36,519,000
Operating expenses
Selling, general and administrative	34,489,000	31,595,000
Research and development	656,000	916,000
Total operating expenses	35,145,000	32,511,000
Operating income	6,581,000	4,008,000
Interest income, net	455,000	78,000
Net income before income taxes	7,036,000	4,086,000
Income tax expense	1,886,000	920,000
Net income	$ 5,150,000	$ 3,166,000
Income per share:
Basic	$ 0.60	$ 0.37
Diluted	$ 0.58	$ 0.36
Weighted-average common shares outstanding:
Basic	8,562,245	8,463,684
Diluted	8,864,585	8,700,833

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2022	$ 85,000	$ 18,308,000	$ 15,780,000	$ 34,173,000
Balance at beginning (in shares) at Jun. 30, 2022	8,475,436
Net income			3,166,000	3,166,000
Issuance of restricted stock, net
Issuance of restricted stock, net (in shares)	28,701
Issuance of common stock upon exercise of options	$ 1,000	82,000		83,000
Issuance of common stock upon exercise of options (in shares)	66,467
Taxes paid on stock option exercised on a net basis		(310,000)		(310,000)
Share-based compensation expense		708,000		708,000
Repurchase of common stock			(153,000)	(153,000)
Repurchase of common stock (in shares)	(15,368)
Ending balance, value at Jun. 30, 2023	$ 86,000	18,788,000	18,793,000	$ 37,667,000
Balance at ending (in shares) at Jun. 30, 2023	8,555,236			8,555,236
Net income			5,150,000	$ 5,150,000
Issuance of restricted stock, net
Issuance of restricted stock, net (in shares)	44,428
Issuance of common stock upon exercise of options	$ 1,000	310,000		311,000
Issuance of common stock upon exercise of options (in shares)	56,580
Share-based compensation expense		1,692,000		1,692,000
Repurchase of common stock			(275,000)	$ (275,000)
Repurchase of common stock (in shares)	(18,361)			(258,356)
Ending balance, value at Jun. 30, 2024	$ 87,000	$ 20,790,000	$ 23,668,000	$ 44,545,000
Balance at ending (in shares) at Jun. 30, 2024	8,637,883			8,637,883

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net income	$ 5,150,000	$ 3,166,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	789,000	550,000
Amortization of finite-life intangible assets	52,000	63,000
Share-based compensation expense	1,692,000	708,000
Deferred income taxes	(571,000)	(43,000)
Changes in operating assets and liabilities:
Accounts receivable	797,000	(3,078,000)
Contract assets	(232,000)	(201,000)
Inventories	459,000	(1,033,000)
Prepaid expenses and other current assets	1,321,000	202,000
Income tax payable	(59,000)	285,000
Accounts payable and accrued liabilities	(1,206,000)	420,000
Accrued compensation	875,000	276,000
Net cash provided by operating activities	9,067,000	1,315,000
Cash Flows from Investing Activities
Expenditures for property and equipment	(287,000)	(1,648,000)
Expenditures for finite-life intangible assets	(108,000)	(68,000)
Net cash used in investing activities	(395,000)	(1,716,000)
Cash Flows from Financing Activities
Issuance of common stock upon exercise of options	311,000	83,000
Taxes paid on stock options exercised on a net basis		(310,000)
Repurchase of common stock	(275,000)	(153,000)
Net cash provided by (used in) financing activities	36,000	(380,000)
Net increase (decrease) in cash	8,708,000	(781,000)
Cash and cash equivalents
Beginning of period	7,372,000	8,153,000
End of period	16,080,000	7,372,000
Supplemental Disclosures of Cash Flow Information
Cash paid for income taxes	2,514,000	676,000
Supplemental Disclosures of Noncash Investing and Financing Activities
Property and equipment acquisitions in accounts payable	4,000	60,000
Intangible asset acquisitions in accounts payable		4,000
Lease assets obtained in exchange for new operating lease liabilities		120,000
Demonstration equipment transferred from inventory to property and equipment	$ 50,000	$ 10,000

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Summary of Significant Accounting Policies	Note 1. Nature of Business and Summary of Significant Accounting Policies Nature of business: 470,000 424,000 Since its inception, the Company has operated in a single industry segment: developing, manufacturing, and marketing medical equipment. A summary of the Company’s significant accounting policies follows: Use of estimates Revenue recognition Shipping and handling expense 383,000 896,000 Cash and cash equivalents Accounts receivable Contract assets Inventories Property and equipment Leases Finite-life intangible assets Long-lived assets The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset’s or assets group’s carrying amount over its estimated fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and finite-life intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets. Warranty liability Changes in the Company’s warranty liability were as follows Schedule of changes in warranty liability Years Ended June 30, 2024 2023 Beginning warranty reserve $ 1,378,000 $ 1,256,000 Accrual for products sold 559,000 416,000 Expenditures and costs incurred for warranty claims (370,000 ) (294,000 ) Ending warranty reserve $ 1,567,000 $ 1,378,000 Income taxes The Company recognizes tax liabilities when the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. Research and development Advertising costs 1,487,000 1,244,000 Share-based payments Fair value of financial instruments Net income per common share 302,340 237,149 288,792 194,154 Recently Issued Accounting Standards Accounting Standards Update (“ASU”) 2016-13 – Credit Losses: Measurement of Credit Losses on Financial Instruments (subsequently amended by ASU 2018-19, 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02) The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. This standard was adopted July 1, 2023 and does not have a material impact on the financial statements. ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The standard introduces increased disclosure requirements primarily related to significant segment expenses, along with disclosure of key criteria and metrics utilized by the Chief Operating Decision Maker (“CODM”). It is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company is currently evaluating the impact of adoption and additional disclosure requirements. ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures The standard introduces increased transparency about income tax information through the requirement of increased disclosures around specific categories in the rate reconciliation and requiring additional information on reconciling items. It is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adoption and additional disclosure requirements.

Revenues

Revenues	12 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenues	Note 2. Revenues Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met. The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the SmartVest System after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues in the Statements of Operations. The timing of revenue recognition, billings and cash collections results in accounts receivable on the Balance Sheets as further described above under Accounts receivable Contract assets Disaggregation of revenues. Schedule of disaggregated revenue Years Ended June 30, 2024 2023 Homecare $ 49,503,000 $ 43,945,000 Hospital 2,535,000 2,080,000 Homecare distributor 1,852,000 1,618,000 Other 826,000 424,000 Total $ 54,716,000 $ 48,067,000 In the following table, homecare revenue is disaggregated by payer type: Years Ended June 30, 2024 2023 Commercial $ 24,215,000 $ 18,481,000 Medicare 18,627,000 18,682,000 Medicare Supplemental 4,706,000 5,000,000 Medicaid 1,114,000 941,000 Other 841,000 841,000 Total $ 49,503,000 $ 43,945,000 Revenues are recognized at a point in time when control passes to the customer upon product shipment or delivery. Performance obligations and transaction price. Homecare market The Company makes available to its homecare patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the homecare market consist of a single performance obligation: the SmartVest System. Homecare patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System. Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long-standing business practice to regard all homecare agreements as transferring control to the patient upon shipment or delivery, despite possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For homecare sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies. As a result, the Company’s product sales qualify for point-in-time revenue recognition. Control transfers to the patient, and revenue is recognized upon shipment or delivery of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivable Contract assets The Company’s contractually stated transaction prices in the homecare market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments. Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information including historical collection patterns to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal. For each type of variable consideration discussed above, there are many contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration. The Company often receives payment from third-party payers for the SmartVest System sales that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs, the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time. Homecare distributors. Hospital market. ● Outright sale – Under these transactions, the Company sells its products for a prescribed or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and payment is made within normal credit terms, usually within 30 days. ● Wrap usage agreements – Under these transactions, the Company provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned to the Company, where it can be refurbished and used again later. Revenue for the consumable wraps is recognized when control transfers to the customer. Other Revenue. Product warranty. Contract balances. Schedule of contract assets June 30, 2024 2023 Receivables, included in “Accounts receivable, net of allowance for credit losses” $ 23,333,000 $ 24,130,000 Contract Assets $ 719,000 $ 487,000 Total Accounts receivable, net of allowances for credit losses, as of June 30, 2022 were $21,052,000. Significant changes in contract assets during the period are as follows: Year Ended June 30, 2024 Year Ended June 30, 2023 Increase (decrease) Increase (decrease) Contract assets, beginning $ 487,000 $ 286,000 Reclassification of contract assets to accounts receivable (2,325,000 ) (1,220,000 ) Contract assets recognized 2,840,000 1,351,000 Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period (283,000 ) 70,000 Contract assets, ending $ 719,000 $ 487,000

Inventories

Inventories	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Note 3. Inventories The components of inventory were as follows: Schedule of components of inventories June 30, 2024 2023 Parts inventory $ 2,556,000 $ 3,420,000 Work in process 454,000 470,000 Finished goods 834,000 323,000 Estimated inventory to be returned 265,000 265,000 Less: Reserve for obsolescence (397,000 ) (257,000 ) Total $ 3,712,000 $ 4,221,000

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4. Property and Equipment Property and equipment were as follows: Schedule of property and equipment, including assets under capital leases Estimated Useful June 30, 2024 2023 Building and building improvements 15 40 $ 3,448,000 $ 3,427,000 Land N/A 200,000 200,000 Land improvements 15 20 173,000 173,000 Equipment 3 10 3,101,000 3,024,000 Software 3 7 2,236,000 2,166,000 Demonstration and rental equipment 3 1,105,000 1,090,000 Construction in progress N/A 72,000 8,000 10,335,000 10,088,000 Less: Accumulated depreciation (5,170,000 ) (4,416,000 ) Net property and equipment $ 5,165,000 $ 5,672,000

Finite-life Intangible Assets

Finite-life Intangible Assets	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-life Intangible Assets	Note 5. Finite-life Intangible Assets The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 12 273,000 224,000 The activity and net balances of finite-life intangible assets were as follows: Schedule of activity and balances of finite-life intangible assets Years Ended June 30, 2024 2023 Balance, beginning $ 605,000 $ 599,000 Additions 104,000 69,000 Amortization expense (52,000 ) (63,000 ) Balance, ending $ 657,000 $ 605,000 Based on the carrying value as of June 30, 2024, future amortization is expected to be as follows: Schedule of future amortization of finite-life intangible assets Fiscal years ending June 30: 2025 $ 49,000 2026 49,000 2027 48,000 2028 47,000 2029 44,000 Thereafter 420,000 Total $ 657,000

Financing Arrangements

Financing Arrangements	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Financing Arrangements	Note 6. Financing Arrangements The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December 13, 2023 2,500,000 no 8.50 1.0 2,500,000 57.0 December 18, 2025 2,500,000 The documents governing the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $ 10,125,000

Common Stock

Common Stock	12 Months Ended
	Jun. 30, 2024
Common Stock
Common Stock	Note 7. Common Stock Authorized shares: 15,000,000 13,000,000 0.01 2,000,000 On May 26, 2021, the Company’s Board of Directors (the “Board”) approved a stock repurchase authorization. Under the authorization, the Company was originally able to repurchase up to $ 3.0 258,356 3,000,000 11.61

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Note 8. Share-Based Compensation Share-based compensation expense for fiscal 2024 and 2023 was $ 1,692,000 708,000 1,659,000 3.0 1.99 2.59 Employee options: 850,000 458,973 1,100 1,031,734 The Company recognizes compensation expense related to share-based payment transactions in the financial statements based on the estimated fair value of the award issued. The fair value of each option is estimated using the Black-Scholes pricing model at the time of award grant. The Company estimates the expected life of options based on the expected holding period by the option holder. The risk-free interest rate is based upon observed U.S. Treasury interest rates for the expected term of the options. The Company makes assumptions with respect to expected stock price volatility based upon the historical volatility of its stock price. Forfeitures are accounted for as they occur. The following assumptions were used to estimate the fair value of options granted: Schedule of assumptions used to estimate fair value of options granted Years Ended June 30, 2024 2023 Risk-free interest rate 3.85 4.64 2.88 4.23 Expected term (years) 6 6 Expected volatility 51 52 53 54 The following table presents employee stock option activity for fiscal 2024 and 2023: Schedule of stock option transactions Number of Shares Weighted- Average Grant Date Fair Value Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in Years) Options outstanding as of June 30, 2022 502,084 $ 3.71 $ 5.82 5.35 Granted 104,325 $ 5.35 $ 9.93 — Exercised (101,357 ) $ 1.44 $ 2.21 — Canceled or forfeited (53,482 ) $ 6.33 $ 11.29 — Options outstanding as of June 30, 2023 451,570 $ 4.28 $ 6.93 5.53 Options exercisable as of June 30, 2023 377,875 $ 4.00 $ 6.25 4.90 Granted 263,162 $ 5.78 $ 10.70 — Exercised (56,580 ) $ 3.66 $ 5.50 — Canceled or forfeited (23,079 ) $ 5.81 $ 10.46 — Options outstanding as of June 30, 2024 635,073 $ 4.91 $ 8.49 6.40 Options exercisable as of June 30, 2024 378,270 $ 4.34 $ 7.03 4.68 The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds its exercise price. At June 30, 2024, the weighted average remaining contractual term for all outstanding stock options was 6.4 4,154,000 635,073 378,270 3,029,000 Restricted stock: The Company issued restricted stock awards to employees totaling 23,428 32,400 three 10.74 9.92 21,000 21,000 10.44 9.86 Schedule of restricted stock transactions Shares of Restricted Stock Weighted-Average Grant Date Fair Value per Share Unvested awards outstanding as of June 30, 2022 34,684 $ 12.59 Granted 53,400 $ 9.90 Vested (45,152 ) $ 11.05 Canceled or forfeited (24,699 ) $ 11.33 Unvested awards outstanding as of June 30, 2023 18,233 $ 10.23 Granted 44,428 $ 10.60 Vested (40,034 ) $ 10.45 Canceled or forfeited — — Unvested awards outstanding as of June 30, 2024 22,627 $ 10.57 Performance-Based Restricted Stock Units The Company granted 175,000 The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years. The weighted average grant date fair value per unit was $ 6.58 175,000 863,000 3.00

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes Components of the provision for income taxes were as follows: Schedule of components of the provision for income taxes Years Ended June 30, 2024 2023 Current: Current Federal $ 1,935,000 $ 744,000 Current State 522,000 219,000 Total Current 2,457,000 963,000 Deferred: Deferred Federal (516,000 ) (20,000 ) Deferred State (55,000 ) (23,000 ) Total Deferred (571,000 ) (43,000 ) Total Income Tax Expense $ 1,886,000 $ 920,000 Actual income tax expense differs from the expected tax expense, computed by applying the statutory federal income tax rate to the Company’s earnings before income taxes, as follows: Schedule of effective income tax reconciliation Years Ended June 30, 2024 2023 Tax expense at statutory federal rate $ 1,477,000 $ 858,000 State income tax expense, net of federal tax effect 369,000 155,000 Share based compensation (82,000 ) (212,000 ) Disallowed meal expenses 169,000 69,000 Change in valuation allowance on deferred tax assets — 11,000 Other permanent items (47,000 ) 39,000 Income tax expense $ 1,886,000 $ 920,000 The effective tax rates for fiscal 2024 and 2023 were 26.8 22.5 The significant components of deferred income taxes were as follows: Schedule of significant components of deferred income taxes June 30, 2024 2023 Deferred tax assets: Revenue recognition and accounts receivable reserves $ 1,361,000 $ 1,292,000 Accrued liabilities 335,000 252,000 Finite-life intangible assets 262,000 126,000 Stock based compensation 768,000 516,000 Tax credits 258,000 221,000 Other 77,000 35,000 Subtotal 3,061,000 2,442,000 Less: Valuation allowance (258,000 ) (221,000 ) Net deferred tax assets 2,803,000 2,221,000 Deferred tax liabilities: Property and equipment (651,000 ) (640,000 ) Total deferred tax liabilities (651,000 ) (640,000 ) Net deferred tax assets $ 2,152,000 $ 1,581,000 The Company has research and development state tax credit carryforwards of $ 258,000 221,000 258,000 221,000 The Company applies the accounting standard for uncertain tax positions pursuant to which a more-likely-than-not threshold is utilized to determine the recognition and derecognition of uncertain tax positions. Once the more-likely-than-not threshold is met, the amount of benefit to be recognized is the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement. It further requires that a change in judgment related to the expected ultimate resolution of uncertain tax positions be recognized in earnings in the period of such a change. The Company does not believe that it has any material uncertain tax positions as of June 30, 2024, and June 30, 2023. The Company is subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. With limited exceptions, the Company is no longer subject to federal and state income tax examinations by tax authorities for fiscal year ended prior to June 30, 2021. The Internal Revenue Service has completed its examination of the Company’s U.S. federal income tax return for the fiscal year ended June 30, 2021, without proposing any adjustments. The Company is not under any current income tax examinations by any other state or local taxing authority. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

Leases

Leases	12 Months Ended
	Jun. 30, 2024
Leases
Leases	Note 10. Leases The Company has leases for office and warehouse space and office equipment that require monthly payments. These leases have payments ranging from $ 200 5,300 The Company has recognized right of use assets associated with its operating leases of $ 87,000 161,000 As of June 30, 2024, and June 30, 2023, the Company had a weighted-average lease term of 1.1 1.5 4.0 4.0 78,000 Maturities of lease liabilities, which are included in other accrued liabilities and other long-term liabilities on the Balance Sheet, are as follows: Schedule of maturities of lease liabilities Fiscal years ending June 30: 2025 $ 80,000 2026 9,000 Total lease payments 89,000 Less: Interest (2,000 ) Present value of lease liabilities $ 87,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies Litigation: 401(k) Profit Sharing Plan: 21 598,000 524,000 Employment Agreements:

Related Parties

Related Parties	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Parties	Note 12. Related Parties The Company uses a parts supplier whose founder and president was a director of the Company through November 12, 2021. The former director has remained a beneficial owner of greater than 5% of the Company’s outstanding common stock through June 30, 2024. The Company made payments to the supplier of $ 2,051,000 1,857,000 18,000 247,000

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 13. Segment Reporting Our President and Chief Executive Officer is our chief operating decision maker (“CODM”). The CODM reviews financial information, including long-lived assets, presented on a consolidated basis, accompanied by information about revenue by market, for purposes of allocating resources and evaluating financial performance. We have a single active product and engage in the single business activity of [selling and supporting that single product]. There are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated level. Accordingly, we have determined that we have a single reportable and operating segment structure. We and our CODM evaluate performance based on revenue from our single product in the markets in which the Company operates. Revenue by market is described above in Note 2.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events The Company evaluates, as of each reporting period, events or transactions that occur after the balance sheet date through the date the financial statements are issued for either disclosure or adjustment to the Company’s financial results. Except as described below, there have been no events subsequent to June 30, 2024, which would require recognition in the Financial Statements or Notes to the Financial Statements.

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of estimates	Use of estimates
Revenue recognition	Revenue recognition
Shipping and handling expense	Shipping and handling expense 383,000 896,000
Cash and cash equivalents	Cash and cash equivalents
Accounts receivable	Accounts receivable
Contract assets	Contract assets
Inventories	Inventories
Property and equipment	Property and equipment
Leases	Leases
Finite-life intangible assets	Finite-life intangible assets
Long-lived assets	Long-lived assets The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset’s or assets group’s carrying amount over its estimated fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and finite-life intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets.
Warranty liability	Warranty liability Changes in the Company’s warranty liability were as follows Schedule of changes in warranty liability Years Ended June 30, 2024 2023 Beginning warranty reserve $ 1,378,000 $ 1,256,000 Accrual for products sold 559,000 416,000 Expenditures and costs incurred for warranty claims (370,000 ) (294,000 ) Ending warranty reserve $ 1,567,000 $ 1,378,000
Income taxes	Income taxes The Company recognizes tax liabilities when the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense.
Research and development	Research and development
Advertising costs	Advertising costs 1,487,000 1,244,000
Share-based payments	Share-based payments
Fair value of financial instruments	Fair value of financial instruments
Net income per common share	Net income per common share 302,340 237,149 288,792 194,154
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting Standards Update (“ASU”) 2016-13 – Credit Losses: Measurement of Credit Losses on Financial Instruments (subsequently amended by ASU 2018-19, 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02) The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. This standard was adopted July 1, 2023 and does not have a material impact on the financial statements. ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The standard introduces increased disclosure requirements primarily related to significant segment expenses, along with disclosure of key criteria and metrics utilized by the Chief Operating Decision Maker (“CODM”). It is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company is currently evaluating the impact of adoption and additional disclosure requirements. ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures The standard introduces increased transparency about income tax information through the requirement of increased disclosures around specific categories in the rate reconciliation and requiring additional information on reconciling items. It is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adoption and additional disclosure requirements.

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of changes in warranty liability	Changes in the Company’s warranty liability were as follows Schedule of changes in warranty liability Years Ended June 30, 2024 2023 Beginning warranty reserve $ 1,378,000 $ 1,256,000 Accrual for products sold 559,000 416,000 Expenditures and costs incurred for warranty claims (370,000 ) (294,000 ) Ending warranty reserve $ 1,567,000 $ 1,378,000

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue	Disaggregation of revenues. Schedule of disaggregated revenue Years Ended June 30, 2024 2023 Homecare $ 49,503,000 $ 43,945,000 Hospital 2,535,000 2,080,000 Homecare distributor 1,852,000 1,618,000 Other 826,000 424,000 Total $ 54,716,000 $ 48,067,000 In the following table, homecare revenue is disaggregated by payer type: Years Ended June 30, 2024 2023 Commercial $ 24,215,000 $ 18,481,000 Medicare 18,627,000 18,682,000 Medicare Supplemental 4,706,000 5,000,000 Medicaid 1,114,000 941,000 Other 841,000 841,000 Total $ 49,503,000 $ 43,945,000
Schedule of contract assets	Contract balances. Schedule of contract assets June 30, 2024 2023 Receivables, included in “Accounts receivable, net of allowance for credit losses” $ 23,333,000 $ 24,130,000 Contract Assets $ 719,000 $ 487,000 Total Accounts receivable, net of allowances for credit losses, as of June 30, 2022 were $21,052,000. Significant changes in contract assets during the period are as follows: Year Ended June 30, 2024 Year Ended June 30, 2023 Increase (decrease) Increase (decrease) Contract assets, beginning $ 487,000 $ 286,000 Reclassification of contract assets to accounts receivable (2,325,000 ) (1,220,000 ) Contract assets recognized 2,840,000 1,351,000 Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period (283,000 ) 70,000 Contract assets, ending $ 719,000 $ 487,000

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of components of inventories	The components of inventory were as follows: Schedule of components of inventories June 30, 2024 2023 Parts inventory $ 2,556,000 $ 3,420,000 Work in process 454,000 470,000 Finished goods 834,000 323,000 Estimated inventory to be returned 265,000 265,000 Less: Reserve for obsolescence (397,000 ) (257,000 ) Total $ 3,712,000 $ 4,221,000

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, including assets under capital leases	Property and equipment were as follows: Schedule of property and equipment, including assets under capital leases Estimated Useful June 30, 2024 2023 Building and building improvements 15 40 $ 3,448,000 $ 3,427,000 Land N/A 200,000 200,000 Land improvements 15 20 173,000 173,000 Equipment 3 10 3,101,000 3,024,000 Software 3 7 2,236,000 2,166,000 Demonstration and rental equipment 3 1,105,000 1,090,000 Construction in progress N/A 72,000 8,000 10,335,000 10,088,000 Less: Accumulated depreciation (5,170,000 ) (4,416,000 ) Net property and equipment $ 5,165,000 $ 5,672,000

Finite-life Intangible Assets (

Finite-life Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of activity and balances of finite-life intangible assets	The activity and net balances of finite-life intangible assets were as follows: Schedule of activity and balances of finite-life intangible assets Years Ended June 30, 2024 2023 Balance, beginning $ 605,000 $ 599,000 Additions 104,000 69,000 Amortization expense (52,000 ) (63,000 ) Balance, ending $ 657,000 $ 605,000
Schedule of future amortization of finite-life intangible assets	Based on the carrying value as of June 30, 2024, future amortization is expected to be as follows: Schedule of future amortization of finite-life intangible assets Fiscal years ending June 30: 2025 $ 49,000 2026 49,000 2027 48,000 2028 47,000 2029 44,000 Thereafter 420,000 Total $ 657,000

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of assumptions used to estimate fair value of options granted	The following assumptions were used to estimate the fair value of options granted: Schedule of assumptions used to estimate fair value of options granted Years Ended June 30, 2024 2023 Risk-free interest rate 3.85 4.64 2.88 4.23 Expected term (years) 6 6 Expected volatility 51 52 53 54
Schedule of stock option transactions	The following table presents employee stock option activity for fiscal 2024 and 2023: Schedule of stock option transactions Number of Shares Weighted- Average Grant Date Fair Value Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in Years) Options outstanding as of June 30, 2022 502,084 $ 3.71 $ 5.82 5.35 Granted 104,325 $ 5.35 $ 9.93 — Exercised (101,357 ) $ 1.44 $ 2.21 — Canceled or forfeited (53,482 ) $ 6.33 $ 11.29 — Options outstanding as of June 30, 2023 451,570 $ 4.28 $ 6.93 5.53 Options exercisable as of June 30, 2023 377,875 $ 4.00 $ 6.25 4.90 Granted 263,162 $ 5.78 $ 10.70 — Exercised (56,580 ) $ 3.66 $ 5.50 — Canceled or forfeited (23,079 ) $ 5.81 $ 10.46 — Options outstanding as of June 30, 2024 635,073 $ 4.91 $ 8.49 6.40 Options exercisable as of June 30, 2024 378,270 $ 4.34 $ 7.03 4.68
Schedule of restricted stock transactions	Schedule of restricted stock transactions Shares of Restricted Stock Weighted-Average Grant Date Fair Value per Share Unvested awards outstanding as of June 30, 2022 34,684 $ 12.59 Granted 53,400 $ 9.90 Vested (45,152 ) $ 11.05 Canceled or forfeited (24,699 ) $ 11.33 Unvested awards outstanding as of June 30, 2023 18,233 $ 10.23 Granted 44,428 $ 10.60 Vested (40,034 ) $ 10.45 Canceled or forfeited — — Unvested awards outstanding as of June 30, 2024 22,627 $ 10.57

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of components of the provision for income taxes	Components of the provision for income taxes were as follows: Schedule of components of the provision for income taxes Years Ended June 30, 2024 2023 Current: Current Federal $ 1,935,000 $ 744,000 Current State 522,000 219,000 Total Current 2,457,000 963,000 Deferred: Deferred Federal (516,000 ) (20,000 ) Deferred State (55,000 ) (23,000 ) Total Deferred (571,000 ) (43,000 ) Total Income Tax Expense $ 1,886,000 $ 920,000
Schedule of effective income tax reconciliation	Actual income tax expense differs from the expected tax expense, computed by applying the statutory federal income tax rate to the Company’s earnings before income taxes, as follows: Schedule of effective income tax reconciliation Years Ended June 30, 2024 2023 Tax expense at statutory federal rate $ 1,477,000 $ 858,000 State income tax expense, net of federal tax effect 369,000 155,000 Share based compensation (82,000 ) (212,000 ) Disallowed meal expenses 169,000 69,000 Change in valuation allowance on deferred tax assets — 11,000 Other permanent items (47,000 ) 39,000 Income tax expense $ 1,886,000 $ 920,000
Schedule of significant components of deferred income taxes	The significant components of deferred income taxes were as follows: Schedule of significant components of deferred income taxes June 30, 2024 2023 Deferred tax assets: Revenue recognition and accounts receivable reserves $ 1,361,000 $ 1,292,000 Accrued liabilities 335,000 252,000 Finite-life intangible assets 262,000 126,000 Stock based compensation 768,000 516,000 Tax credits 258,000 221,000 Other 77,000 35,000 Subtotal 3,061,000 2,442,000 Less: Valuation allowance (258,000 ) (221,000 ) Net deferred tax assets 2,803,000 2,221,000 Deferred tax liabilities: Property and equipment (651,000 ) (640,000 ) Total deferred tax liabilities (651,000 ) (640,000 ) Net deferred tax assets $ 2,152,000 $ 1,581,000

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2024
Leases
Schedule of maturities of lease liabilities	Maturities of lease liabilities, which are included in other accrued liabilities and other long-term liabilities on the Balance Sheet, are as follows: Schedule of maturities of lease liabilities Fiscal years ending June 30: 2025 $ 80,000 2026 9,000 Total lease payments 89,000 Less: Interest (2,000 ) Present value of lease liabilities $ 87,000

Schedule of changes in warranty

Schedule of changes in warranty liability (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning warranty reserve	$ 1,378,000	$ 1,256,000
Accrual for products sold	559,000	416,000
Expenditures and costs incurred for warranty claims	(370,000)	(294,000)
Ending warranty reserve	$ 1,567,000	$ 1,378,000

Nature of Business and Summar_4

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	$ 54,716,000	$ 48,067,000
Cost of revenues	12,990,000	11,548,000
Advertising, marketing and trade show costs	$ 1,487,000	$ 1,244,000
Common stock equivalents included from calculation of diluted earnings per share	302,340	237,149
Antidilutive securities excluded from computation of earnings per share	288,792	194,154
Shipping and Handling [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of revenues	$ 383,000	$ 896,000
International [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	$ 470,000	$ 424,000

Schedule of disaggregated reven

Schedule of disaggregated revenue (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 54,716,000	$ 48,067,000
Home Care [Member]
Disaggregation of Revenue [Line Items]
Revenue	49,503,000	43,945,000
Home Care [Member] | Commercial [Member]
Disaggregation of Revenue [Line Items]
Revenue	24,215,000	18,481,000
Home Care [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue	18,627,000	18,682,000
Home Care [Member] | Medicare Supplemental [Member]
Disaggregation of Revenue [Line Items]
Revenue	4,706,000	5,000,000
Home Care [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,114,000	941,000
Home Care [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue	841,000	841,000
Hospital [Member]
Disaggregation of Revenue [Line Items]
Revenue	2,535,000	2,080,000
Home Care Distributor [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,852,000	1,618,000
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 826,000	$ 424,000

Schedule of contract assets (De

Schedule of contract assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Receivables, included in “Accounts receivable, net of allowance for credit losses”	$ 23,333,000	$ 24,130,000
Contract Assets	719,000	487,000
Contract assets beginning	487,000	286,000
Reclassification of contract assets to accounts receivable	(2,325,000)	(1,220,000)
Contract assets recognized	2,840,000	1,351,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period	(283,000)	70,000
Contract assets, ending	$ 719,000	$ 487,000

Schedule of components of inven

Schedule of components of inventories (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Parts inventory	$ 2,556,000	$ 3,420,000
Work in process	454,000	470,000
Finished goods	834,000	323,000
Estimated inventory to be returned	265,000	265,000
Less: Reserve for obsolescence	(397,000)	(257,000)
Total	$ 3,712,000	$ 4,221,000

Schedule of property and equipm

Schedule of property and equipment, including assets under capital leases (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 10,335,000	$ 10,088,000
Less: Accumulated depreciation	(5,170,000)	(4,416,000)
Net property and equipment	5,165,000	5,672,000
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,448,000	3,427,000
Building and Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Building and Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Land [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 200,000	200,000
Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 173,000	173,000
Land Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Land Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	20 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,101,000	3,024,000
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,236,000	2,166,000
Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Demonstration and Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Gross property and equipment	$ 1,105,000	1,090,000
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 72,000	$ 8,000

Schedule of activity and balanc

Schedule of activity and balances of finite-life intangible assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Balance, beginning	$ 605,000	$ 599,000
Additions	104,000	69,000
Amortization expense	(52,000)	(63,000)
Balance, ending	$ 657,000	$ 605,000

Schedule of future amortization

Schedule of future amortization of finite-life intangible assets (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 49,000
2026	49,000
2027	48,000
2028	47,000
2029	44,000
Thereafter	420,000
Total	$ 657,000	$ 605,000	$ 599,000

Finite-life Intangible Assets_2

Finite-life Intangible Assets (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 273,000	$ 224,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	12 years

Financing Arrangements (Details

Financing Arrangements (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Line of Credit Facility [Line Items]
Minimum tangible net worth to be maintained	$ 10,125,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility effective date	Dec. 13, 2023
Maximum borrowing capacity	$ 2,500,000
Line of credit balance	$ 0	$ 0
Basis spread on rate	1%
Borrowing capacity of eligible accounts receivable	$ 2,500,000
Available borrowing capacity	57%
Credit facility expiration date	Dec. 18, 2025
Available borrowing capacity	$ 2,500,000
Revolving Credit Facility [Member] | Prime Rate [Member]
Line of Credit Facility [Line Items]
Interest rate	8.50%

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	May 26, 2021
Common stock, authorized	13,000,000	13,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Number of share repurchased	258,356
Repurchase of common stock	$ (275,000)	$ (153,000)
Share price	$ 11.61
Board of Directors Chairman [Member]
Common stock, authorized			3,000,000
Common Stock [Member]
Common stock, authorized	13,000,000
Common stock, par value (in dollars per share)	$ 0.01
Number of share repurchased	18,361	15,368
Repurchase of common stock
Capital Stock [Member]
Common stock, authorized	15,000,000
Authorized Shares Undesignated Stock [Member]
Common stock, authorized	2,000,000

Schedule of assumptions used to

Schedule of assumptions used to estimate fair value of options granted (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Risk free interest rate - minimum	3.85%	2.88%
Risk free interest rate - maximum	4.64%	4.23%
Expected term (years)	6 years	6 years
Expected volatility - minimum	51%	53%
Expected volatility - maximum	52%	54%

Schedule of stock option transa

Schedule of stock option transactions (Details) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option outstanding, ending	635,073
Option outstanding, ending	378,270
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, beginning	451,570	502,084
Weighted average grant date fair value, beginning	$ 4.28	$ 3.71
Weighted average exercise price, beginning	$ 6.93	$ 5.82
Options outstanding at beginning (in years)		5 years 4 months 6 days
Options exercisable, granted	263,162	104,325
Options exercisable, granted	$ 5.78	$ 5.35
Options exercisable, granted	$ 10.70	$ 9.93
Options exercisable, exercised	(56,580)	(101,357)
Options exercisable, exercised	$ 3.66	$ 1.44
Options exercisable, exercised	$ 5.50	$ 2.21
Options exercisable, canceled or forfeited	(23,079)	(53,482)
Options exercisable, canceled or forfeited	$ 5.81	$ 6.33
Options exercisable, canceled or forfeited	$ 10.46	$ 11.29
Option outstanding, ending	635,073	451,570
Weighted average grant date fair value, ending	$ 4.91	$ 4.28
Weighted average exercise price, ending	$ 8.49	$ 6.93
Option outstanding at ending (in Years)	6 years 4 months 24 days	5 years 4 months 6 days
Option outstanding, ending	378,270	377,875
Options exercisable , ending	$ 4.34	$ 4
Options exercisable , ending	$ 7.03	$ 6.25
Option exercisable at ending		4 years 10 months 25 days
Options exercisable, ending (in years)	4 years 8 months 5 days

Schedule of restricted stock tr

Schedule of restricted stock transactions (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, beginning	18,233	34,684
Outstanding, beginning	$ 10.23	$ 12.59
Granted	44,428	53,400
Granted	$ 10.60	$ 9.90
Vested	(40,034)	(45,152)
Vested	$ 10.45	$ 11.05
Canceled or forfeited		(24,699)
Canceled or forfeited		$ 11.33
Outstanding, ending	22,627	18,233
Weighted average grant date fair value, ending	$ 10.57

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation expense	$ 1,692,000	$ 708,000
Unrecognized compensation expense	$ 1,659,000
Unrecognized compensation expense, period for recognition	6 years 4 months 24 days
Options exercisable, intrinsic value	$ 4,154,000
Shares outstanding	635,073
Vested and exercisable	378,270
Options exercisable, intrinsic value	$ 3,029,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of per share	$ 10.74	$ 9.92
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding	635,073	451,570	502,084
Vested and exercisable	378,270	377,875
Granted	263,162	104,325
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense	$ 863,000
Unrecognized compensation expense, period for recognition	3 years
Shares outstanding	175,000
Granted	175,000
Other description	The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years.
Weighted Average Grant Date Fair Value Per Unit	$ 6.58
Current Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for issuance	850,000
Options outstanding (shares)		1,100
Available for grant, shares	1,031,734
Prior Plans [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted under the 2017 plan	458,973
Employee [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued	23,428	32,400
Employee [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting term	3 years
Directors [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued	21,000	21,000
Fair value of per share	$ 10.44	$ 9.86
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	3 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	1 year 11 months 26 days
Weighted Average [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	2 years 7 months 2 days

Schedule of components of the p

Schedule of components of the provision for income taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Current:
Current Federal	$ 1,935,000	$ 744,000
Current State	522,000	219,000
Total Current	2,457,000	963,000
Deferred:
Deferred Federal	(516,000)	(20,000)
Deferred State	(55,000)	(23,000)
Total Deferred	(571,000)	(43,000)
Total Income Tax Expense	$ 1,886,000	$ 920,000

Schedule of effective income ta

Schedule of effective income tax reconciliation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Tax expense at statutory federal rate	$ 1,477,000	$ 858,000
State income tax expense, net of federal tax effect	369,000	155,000
Share-Based Payment Arrangement, Noncash Expense	1,692,000	708,000
Disallowed meal expenses	169,000	69,000
Change in valuation allowance on deferred tax assets		11,000
Other permanent items	(47,000)	39,000
Income tax expense	$ 1,886,000	$ 920,000

Schedule of significant compone

Schedule of significant components of deferred income taxes (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Deferred tax assets:
Revenue recognition and accounts receivable reserves	$ 1,361,000	$ 1,292,000
Accrued liabilities	335,000	252,000
Finite-life intangible assets	262,000	126,000
Stock based compensation	768,000	516,000
Tax credits	258,000	221,000
Other	77,000	35,000
Subtotal	3,061,000	2,442,000
Less: Valuation allowance	(258,000)	(221,000)
Net deferred tax assets	2,803,000	2,221,000
Deferred tax liabilities:
Property and equipment	(651,000)	(640,000)
Total deferred tax liabilities	(651,000)	(640,000)
Net deferred tax assets	$ 2,152,000	$ 1,581,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Effective tax rate	26.80%	22.50%
Valuation allowance	$ 258,000	$ 221,000
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Tax credit carryforwards	$ 258,000	$ 221,000

Schedule of maturities of lease

Schedule of maturities of lease liabilities (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Leases
2025	$ 80,000
2026	9,000
Total lease payments	89,000
Less: Interest	(2,000)
Present value of lease liabilities	$ 87,000	$ 161,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Operating lease payment	$ 78,000
Present value of lease liabilities	$ 87,000	$ 161,000
Weighted-average lease term	1 year 1 month 6 days	1 year 6 months
Weighted-average discount rate	4%	4%
Office And Warehouse Space [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Operating lease payment	$ 200
Office And Warehouse Space [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Operating lease payment	$ 5,300

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Employee benefit plan, minimum age requirement	21 years
Employee benefit plan, employer contribution	$ 598,000	$ 524,000

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Related Party Transactions [Abstract]
Payments to the supplier	$ 2,051,000	$ 1,857,000
Payments due to supplier	$ 18,000	$ 247,000